In our study, protection from pre‐steatotic lipidosis (Figure 2b) paralleled the effect of these treatments on circulating insulin (Figure 4a), which affects hepatic steatosis through regulation of Fasn (hepatic fatty acid synthase) expression (Figure 4c) (Liu et al., 2018). This evidence concerns the gene FASN and fatty liver disease.